Abstract: A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin solid dispersion contains povidone K30, soybean lecithin and acrylic resin IV, and the mass ratio between silymarin and other medical accessories in silymarin solid dispersion is silymarin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silymarin disclosed in this invention is 2.3 times longer while the mean residence time (MRT) of which is 9.
Abstract: To provide a solution for forming a double eyelid which enables extremely easy formation of a natural and ideal double eyelid without giving a displeased feeling or an uncomfortable feeling to a user, and a method for forming a double eyelid using the solution for forming a double eyelid. A solution for forming a double eyelid 1 according to the present invention is formed by dissolving, into a solvent having volatility, a fibrous material which forms a film 1a onto a skin 5a of an eyelid 5 and shrinks with vaporization of the solvent. By applying the solution 1, in a successive-curve form, over an imaginary line I forming a fold 5d of a double eyelid in the eyelid 5 onto which a user want to make a fold and vaporizing the solvent so as to shrink the film 1a, successive concaved groove-like constricted part 5c is formed on the imaginary line I and the fold 5d of a double eyelid along the constricted part 5c is formed.
Abstract: A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition.
Abstract: An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, non-ionic surfactants, humectants, a silicone compound, and water. Also disclosed are methods of using the topical formulations disclosed within this specification to treat either a susceptible or treatment-resistant strain of lice, as well as uses in the manufacture of a medicament for treating or preventing a lice infestation from a susceptible or treatment-resistant strain in a human patient.
Abstract: The disclosure provides granular forms of porous biomaterials and methods for forming and applying these biomaterials, including uses to promote vascularization and tissue ingrowth.
Type:
Grant
Filed:
March 3, 2010
Date of Patent:
January 6, 2015
Assignee:
Healionics Corporation
Inventors:
Max Maginness, Andrew Marshall, Christine L. Glaister, Michel Alvarez
Abstract: The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein.
Abstract: The present invention provides compositions for preventing growth and proliferation of biofilm embedded microorganisms on devices comprising: (a) a cationic polypeptide and (b) a bis-guanide or a salt thereof. The invention further provides methods for preparing medical devices with such compositions.
Abstract: The present invention relates to an intra-oral device including a carrier that has an outside wall, an inside wall and an occlusal wall connecting the outside wall to the inside wall. The carrier has at least one inset and at least one insert carrying a beneficial agent that is adapted to fit the inset, and the beneficial agent is capable of promoting weight loss. The intra-oral device is positioned in a user's mouth so that the intra-oral device is in contact with the user's cheeks, lips and/or tongue and the beneficial agent passes through the mucosal membrane of the user's mouth.
Type:
Grant
Filed:
October 8, 2009
Date of Patent:
December 2, 2014
Assignee:
Dynamic Mouth Devices, L.L.C.
Inventors:
Laura Bardach, James Geduldig, Salvatore Napoli
Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.
Abstract: The invention relates to a method for preparing a two-colour cosmetic product, particularly a two-colour cosmetic product intended for make-up, which consists of a base cosmetic product and a decorative cosmetic product in a different colour being applied onto said base cosmetic product.
Abstract: The present invention is directed to a cosmetic composition containing: (a) at least one propylphenylsilsesquioxane resin; (b) at least one cosmetically-acceptable aromatic solvent; (c) at least one colorant, and (d) optionally, at least one co-solvent, and wherein the composition is substantially free of volatile solvents. Also disclosed is a method of imparting lasting shine onto lips by contacting the lips with the above described composition.
Abstract: A transdermal therapeutic system (TTS) that is essentially composed of two compartments and is provided with activatable oversaturation and controlled permeation promotion. The invention more particularly relates to a TTS wherein an oversaturated active ingredient solution is produced in an active-substance-containing polymer matrix when the system is applied to the skin, caused by the controlled supply of one or several substances promoting the permeation of the pharmaceutical active ingredient; to the two compartments from which the inventive transdermal therapeutic system is assembled; and to the production of the transdermal therapeutic system from the two compartments.
Abstract: Films comprising a liquid-absorbent layer with an adsorbed antimicrobial material and an impermeable layer are provided. The films can be suitable for preparation of tubular casings and shrinkbags such as casings for foodstuffs. Also disclosed are foodstuffs processed in the tubular casing comprising the antimicrobial material.
Abstract: A composite structure suitable for making transdermal delivery devices includes in sequence: (a) a liner film layer; (b) a containment layer having from zero to 15 wt % content of vinyl acetate repeating units, the layer including either a thermal bonding copolyester resin or a combination of an ethylene-vinyl acetate component and a nonpolar polymer; and (c) a polyester film layer less than 20 ?m in thickness. A drug layer lies either between the liner film layer and the containment layer or within a concave depression in the containment layer. A composition including an ethylene-vinyl acetate component and an ABA block copolymer, wherein the A segments of the block copolymer are styrenic segments, is also provided. The composition includes between 1 and 15 wt % of vinyl acetate repeating units, based on the total weight of composition exclusive of any solvents.
Type:
Grant
Filed:
September 24, 2010
Date of Patent:
September 23, 2014
Assignee:
DuPont Teijin Films U.S. Limited Partnership
Inventors:
Peter N. Nugara, Bruce C. Begnoche, Stephen K. Franzyshen, Fenghua Deng, Daniel C. Sanders, Christine A. Creegan, Steven R. Cosentino
Abstract: A composition for pulmonary administration comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an excipient. In one version, the particles have a mass median aerodynamic diameter from about 1 ?m to about 5 ?m, and the fluoroquinolone has a half life in the lungs of at least 1.5 hours. The composition is useful in treating an endobronchial infection, such as Pseudomonas aeruginosa, and is particularly useful in treating cystic fibrosis.
Abstract: Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same are disclosed. The medical article generally comprises an implantable substrate having a coating, and the coating contains a polymer comprising a polymeric product of a reaction comprising a polyol, a polycarboxylic acid, an amino acid and an agent.
Type:
Grant
Filed:
July 16, 2009
Date of Patent:
August 19, 2014
Assignee:
Abbott Cardiovascular Systems Inc.
Inventors:
Stephen D. Pacetti, Charles Claude, Thierry Glauser, Jessica R. DesNoyer, Syed F. A. Hossainy
Abstract: An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, non-ionic surfactants, humectants, a silicone compound, and water. Also disclosed are methods of using the topical formulations disclosed within this specification to treat either a susceptible or treatment-resistant strain of lice, as well as uses in the manufacture of a medicament for treating or preventing a lice infestation from a susceptible or treatment-resistant strain in a human patient.
Abstract: The present invention is directed to heat treated xanthan gums, which have improved solution viscosity over other xanthan gums heat-treated under the same processing conditions while maintaining the improved ease of use and the short, non-stringy gel texture of heat treated xanthan gums. Such high solution viscosity xanthan gums are suitable in a variety of applications, including cosmetic and personal care compositions.
Abstract: Deodorant composition for the treatment of female malodour comprising a perfume containing violet nitrile and optionally pharaone and/or zinarine.
Type:
Grant
Filed:
April 12, 2011
Date of Patent:
July 22, 2014
Assignee:
Givaudan SA
Inventors:
Keith Douglas Perring, John Martin Behan, Alan Forbes Provan